{
    "2021-09-27": [
        [
            {
                "time": "2022-09-30",
                "original_text": "凯莱英：本次限制性股票上市流通日期为9月30日，占公司总股本0.0455%。",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "限制性股票",
                        "上市流通",
                        "解禁"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：政策鼓励医疗器械国产替代，国产器械前景广阔。",
                "features": {
                    "keywords": [
                        "政策鼓励",
                        "医疗器械",
                        "国产替代",
                        "前景广阔"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2022-09-30",
                "original_text": "凯莱英(002821.SZ)：11.12万股限售股将于9月30日起上市流通，解禁。",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "限售股",
                        "解禁",
                        "上市流通"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2022-09-30",
                "original_text": "凯莱英(002821.SZ)：11.122万股限制性股票9月30日解锁上市。",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "限制性股票",
                        "解锁",
                        "上市"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业跨市场周报：新冠呈常态化趋势，看好新冠小分子药CDMO供应商。",
                "features": {
                    "keywords": [
                        "医药生物",
                        "新冠",
                        "常态化",
                        "CDMO供应商"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "新冠药物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：从景气度、竞争力、外需逻辑看诺禾致源投资价值。",
                "features": {
                    "keywords": [
                        "医药生物",
                        "景气度",
                        "竞争力",
                        "外需",
                        "诺禾致源"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "基因检测"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物：海外新冠治疗药物Q4有望获批。",
                "features": {
                    "keywords": [
                        "医药生物",
                        "海外",
                        "新冠治疗药物",
                        "Q4获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物",
                        "新冠药物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}